The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 05, 2002
Filed:
Nov. 25, 1996
Christophorus Joannes Meijer, Leiden, NL;
Adrianus Johannes van den Brule, 's-Hertogenbosch, NL;
Jan Marcus Walboomers, Amsterdam, NL;
Petrus Josephus Snijders, Amstelveen, NL;
Stichting Researchfonds Pathologie, Amsterdam, NL;
Abstract
The oligonucleotides: (i) the 23-mer 5′-TTTGTTACTGTGGTAGATACTAC-3′ (SEQ ID NO: 1) or the 23-mer which is complementary to it; (ii) a 23-mer derived from (i) by from 1 to 5 nucleotide substitutions; (iii) a 23 -mer having a 3′ terminal sequence consisting of (i) or (ii); (iv) a fragment of (i) or (ii) having a length of from 8 to 18 nucleotides; (v) the 25-mer 5′-GAAAAATAAACTGTAAATCATATTC-3′ (SEQ ID NO: 2) or the 25-mer which is complementary to it; (vi) a 25-mer derived from (v) by from 1 to 5 nucleotide substitutions; (vii) a 25 -mer having a 3′ terminal sequence consisting of (v) or (vi); (viii) the 28-mer 5′-GAAAAATAAACTGTAAATCATATTCTTC-3′ (SEQ ID NO: 10) or the 28-mer which is complementary to it; (ix) the 28-mer 5′-GAAAAATAAACTGTAAATCATATTCCTC-3′ (SEQ ID NO: 18) or the 28-mer which is complementary to it; (x) a 28-mer derived from (viii) or (ix) by from 1 to 5 nucleotide substitutions; (xi) a 28 -mer having a 3′ terminal sequence consisting of (viii), (ix) or (x); (xii) a fragment of (v), (vi), (vii), (ix) or (x) having a length of from 8 to 18 nucleotides, useful as a primer in a nuc acid amplification process, e.g. a general primer PCR or NASBA, or LCR, to amplify DNA of genital HPV genotypes, e.g. in a method of analyzing a sample for the presence therein of HPV.